

Table S1. Hypertensive medication and comorbidities

Variables	N (%)
Number of anti-HT medications ≥ 2	3/13 (23)
Type of anti-HT medication:	
• Angiotensin converting enzyme inhibitor	3/13 (23)
• Angiotensin II receptor blocker	6/13 (46)
• Calcium channel blocker	5/13 (39)
• Hydrochlorothiazide	3/13 (23)
Comorbidities:	
• Hyperlipidemia	4/13 (31)
• Depression	1/13 (8)
• Hyperthyreosis	1/13 (8)
• Hypothyreosis	1/13 (8)

HT=Hypertensive

Table S2. Blood pressure status before antihypertensive medication wash-out and after interventions (n=12)

	Screening visit (prior to wash-out of antihypertensive medication)	CPAP	AZT	AZT plus CPAP	P value
Office systolic blood pressure (mmHg)	147 (15)	153 (11)	145 (7)	144 (7)	0.073
Office mean arterial pressure (mmHg)	104 (10)	106 (8)	102 (7)	101 (7)	0.186
Office diastolic blood pressure (mmHg)	82 (10)	83 (9)	80 (10)	80 (8)	0.476
Office heart rate (bpm)	63 (8)	63 (9)	62 (6)	63 (8)	0.994

Data shown as mean (SD).

Table S3. Biochemistry

	CPAP (n=13)		AZT (n=13)		AZT plus CPAP (n=12)		P value
	Pre	Post	Pre	Post	Pre	Post	
pH	7.41 (0.02)	7.40 (0.02)	7.40 (0.01)	7.33 (0.02)	7.40 (0.02)	7.32 (0.03)	<0.001 ^{a,b}
Base excess (mmol/L)	1.7 (1.3)	1.6 (1.6)	2.1 (0.9)	-5.7 (1.5)	1.9 (1.7)	-5.6 (1.8)	<0.001 ^{a,b}
Lactate (mmol/L)	1,27 (0.32)	1.28 (0.24)	1.23 (0.18)	1.25 (0.20)	1.34 (0.26)	1.15 (0.25)	0.28
Hemoglobin (g/L)	141 (19)	138 (14)	141 (12)	146 (11)	138 (11)	143 (12)	0.148
Glucose (mmol/L)	6.59 (1.33)	6.61 (2.07)	6.74 (1.85)	6.86 (2.05)	6.96 (1.69)	6.90 (1.57)	0.91

Data shown as mean (SD). Abbreviations: a= p<0.05 for AZT to CPAP comparison; b= p<0.05 for AZT/CPAP to CPAP comparison; c= p<0.05 AZT to AZT/CPAP comparison.

Table S4. Treatment related side effects

Adverse events n (%)	CPAP (n=13)	AZT (n=13)	AZT plus CPAP (n=12)
Paresthesia	0/13 (0)	6/13 (46)	4/12 (33)
Dysguesia	0/13 (0)	1/13 (8)	0/12 (0)
Diarrhea	0/13 (0)	1/13 (8)	1/12 (8)
Dyspepsia	0/13 (0)	4/13 (31)	3/12 (25)
Nocturia	0/13 (0)	1/13 (8)	1/12 (8)
Decreased libido	0/13 (0)	1/13 (8)	0/12 (0)